Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Extension study of CT-P13 in rheumatoid arthritis patients completing phase I/II trial
jRCT2080222369Phase 2
- Sponsor
- Nippon Kayaku Co., Ltd.
- Start
- Jan 2014
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of infliximab-dyyb in rheumatoid arthritis (RA), sponsored by Nippon Kayaku Co., Ltd.
02
Drugs
infliximab-dyyb
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on jRCT2080222369.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080222369.